RxDoctor Payments Data

Premal Thaker, MD

Gynecologic Oncology · Saint Louis, MONPI 1891739173

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by AstraZeneca at 25.0% of the total. Reporting peaked in 2019 at $106,425 and has fallen 52.4% since, to $50,640 in 2025. Among gynecologic oncology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$286,900in general payments, 2019–2025

Across 289 payments — averaging $992.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$72K
  • GSK$67K
  • Merck$30K
  • Seagen Inc.$17K
  • Incyte Corporation$16K
  • Tesaro, Inc.$16K
  • plus $70K from 26 others
$2,341,582in research payments, 2019–2025

Across 436 payments — averaging $5370.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$609K
  • Genentech, Inc.$571K
  • Seagen Inc.$287K
  • Novocure Inc.$236K
  • Tesaro, Inc.$171K
  • Incyte Corporation$114K
  • plus $353K from 11 others

What the payments were for

  • Consulting fees$158,79255%
  • Speaking & faculty fees$98,50534%
  • Travel & lodging$18,2786%
  • Food & beverage$11,2134%
  • Education$1130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$286,900 in reported general payments places this provider in the 95th percentile of 38 gynecologic oncology providers in Missouri.

See all gynecologic oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$433,584
Medicare patients
249
Services billed
21,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LynparzaOlaparib15$255,056
EliquisApixaban29$20,919
ErtapenemErtapenem Sodium11$3,273
Estradiol20$2,172
Letrozole26$705
Dexamethasone55$695
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$551
Prochlorperazine Maleate56$540
Mirtazapine11$468
Oxycodone Hcl36$433
Tamoxifen Citrate12$409
Gabapentin47$399
Ondansetron Hcl59$290
Duloxetine Hcl19$286
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLynparza$71,702$255,05615 claims
PfizerEliquis$16$20,91929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 gynecologic oncology providers in Missouri.

Other gynecologic oncology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →